Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.

The objective is to evaluate the efficacy and safety of carbon ion radiotherapy (CIRT) combined with nituzumab and gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer.

Trial Details

NCT ID
NCT06840067
Phase
NA
Sponsor
Gansu Wuwei Tumor Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • carbon ion radiotherapy (CIRT)
Locations (sample)
  • Wuwei, Gansu, China|37.92672,102.63202

Key Eligibility Criteria

  • Age ≥18 years and ≤80 years;
  • Indications: patients with locally advanced or metastatic pancreatic adenocarcinoma confirmed by histopathology or cytology (stage III - IV).
  • At least one measurable lesion was present according to RECIST version 1.1 evaluation criteria.
  • Suitable for one cycle of gemcitabine combined with nituzumab.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →